

Amendment to the Claims

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior claim listings.

1. (Currently amended) An expression vector comprising the nucleic acid sequence as illustrated in SEQ ID NO.: 5 ~~or Figure 4; a nucleic acid sequence encoding the amino acid sequence illustrated in SEQ ID NO.: 6 or Figure 5;~~ or a fragment thereof.
2. (Currently Amended) The expression vector of claim 1 or 64 wherein the vector is a plasmid or a viral vector.
3. (Original) The expression vector of claim 2 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
4. (Original) The expression vector of claim 3 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
5. (Original) The expression vector of claim 4 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
6. The expression vector of claim 1 further comprising at least one additional tumor-associated antigen.
7. (Original) The expression vector of claim 6 wherein the vector is a plasmid or a viral vector.
8. (Original) The expression vector of claim 7 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
9. (Original) The expression vector of claim 8 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
10. (Original) The expression vector of claim 9 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
- 11-35. (Cancelled)
36. An isolated peptide derived from BFA5 as shown in Table X or XI.

37. (Currently amended) A method for immunizing a host against the tumor antigen BFA5 comprising administering to the patient a peptide ~~shown in Table X or XI of~~ claim 36, either alone or in combination with another agent, where the individual components of the combination are administered simultaneously or separately from one another.

38-62. (Cancelled)

63. (Currently amended) An antibody having the ability to bind the amino acid sequence of SEQ ID NO.: 6 or a ~~fragment thereof~~ amino acid sequence of SEQ ID NO.: 6.

64. (New) An expression vector comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO.: 6 or a fragment thereof.

65. (New) A composition comprising an expression vector of claim 1 and a pharmaceutically acceptable carrier.

66. (New) A composition comprising an expression vector of claim 64 and a pharmaceutically acceptable carrier.